CN201179222Y - Medicament coating bracket - Google Patents
Medicament coating bracket Download PDFInfo
- Publication number
- CN201179222Y CN201179222Y CNU2008200173570U CN200820017357U CN201179222Y CN 201179222 Y CN201179222 Y CN 201179222Y CN U2008200173570 U CNU2008200173570 U CN U2008200173570U CN 200820017357 U CN200820017357 U CN 200820017357U CN 201179222 Y CN201179222 Y CN 201179222Y
- Authority
- CN
- China
- Prior art keywords
- layer
- medicine
- bioactivator
- supporting frame
- support matrix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
The utility model belongs to the medical appliance field, in particular relates to a medicine coating supporting frame which has the technical proposal that the supporting frame adopts a bioactivator layer which is coated on the supporting frame matrix, and the bioactivator layer is two or three medicine coatings, the medicine is released in different stages and blocks the restenosis from happening from different angles, periods and orientations, and the supporting frame can effectively reduce the vascular restenosis rate after the supporting frame is placed.
Description
Technical field
This utility model belongs to medical instruments field, is specially a kind of coating stent of medicine.
Background technology
From 1900, coronary heart disease just became the No.1 disease of harm Western society, and in recent years, although medical science has obvious improvement, this disease is not only in western countries, also became the common cause of death in China.Percutaneous tranluminal coronary angioplasty (PTCA) and coronary stent are implanted these two kinds of Therapeutic Method of (Stenting) art, are the treatment coronary heart disease effective methods that just grows up in nearly 20 years, have obtained significant progress in recent years.Investigation according to american heart medical association, there was 1,300,000 patient do the coronary artery intracavity forming operation approximately in 1997, half needs of patients placing rack wherein, the combination of this Stent and coronary artery intracavity forming operation has become a kind of trend, especially along with the appearance of drug releasing stent, this trend is with the rate increase in every year 20%.But the restenosis behind the placing rack is a unavoidable problem, and the support of therefore seeking a kind of low restenosis rate is extremely urgent thing.
Rapamycin drug releasing stent and taxol drug discharge the appearance of support, obviously reduced postoperative restenosis rate, but clinically, get involved the cardiovascular doctor and when selecting drug releasing stent, often be difficult to decision, because rapamycin that has at present and taxol drug support, though the mechanism of action difference, clinical effectiveness is on a par, this brings a difficult problem, the injury of also bringing for patient virtually simultaneously for the doctor when selecting support.
The utility model content
The purpose of this utility model is to provide a kind of coating stent of medicine at the shortcoming of above-mentioned existence, this support adopts and applies the bioactivator layer on the support matrix, described bioactivator layer is two-layer or three layers of medication coat structural design, medicine discharged in the different stages, can stop the generation of restenosis in a plurality of links, this kind support can effectively reduce the restenosis rate of placing rack operation back blood vessel.
The technical solution of the utility model is, adopts the structural design of support matrix, bioactivator layer, and described bioactivator layer is two-layer or three layers of medication coat.
Characteristics of the present utility model also have, and described bioactivator layer is microtubule stabilizer layer and the immunosuppressant layer that is coated on the support matrix surface, is two-layer medication coat; Described bioactivator layer is microtubule stabilizer layer and immunosuppressant layer and the anticoagulant layer that is coated on the support matrix surface, and wherein the anticoagulant layer is an outermost layer, is three layers of medication coat; Described microtubule stabilizer layer is the taxol drug layer, and the immunosuppressant layer is the rapamycin medicine layer; Described anticoagulant layer is the heparin medicine layer.
Beneficial effect of the present invention can be by obtaining above-mentioned description, rapamycin and paclitaxel all are fat-soluble, discharge slower, in second of restenosis generation, three phases discharged, the two has identical release profiles, the hypertrophy that can independently effectively suppress endotheliocyte simultaneously again by different approach, during the use in conjunction of two kinds of medicines to preventing the cooperative effect that has of restenosis, low when suppressing the required dosage of restenosis also than single drug simultaneously, it is lower than the toxicity of single drug pair cell under same dosage situation to unite use in addition.Heparin is soluble in water, can in a few hours to a couple of days after support is implanted, discharge, the first phase of taking place at restenosis discharges, thereby can greatly suppress the formation of early stage thrombosis, thereby, in case can be behind the support implant into body in the technical program from different angles, different periods, the generation of multi-faceted blocking-up restenosis.This shows, the utlity model has substantive distinguishing features and progress.
Description of drawings
Fig. 1 is the structural representation of the two-layer medication coat of this utility model,
Fig. 2 is another structural representation of the two-layer medication coat of this utility model,
Fig. 3 is another structural representation of the two-layer medication coat of this utility model,
Fig. 4 is the structural representation of three layers of medication coat of this utility model,
Wherein, 1 is the support matrix, and 2 is the taxol drug layer, and 3 is the rapamycin medicine layer, and 4 is the heparin medicine layer, and 5 is paclitaxel and rapamycin hybrid medicine layer.
The specific embodiment
Below in conjunction with accompanying drawing embodiment of the present utility model is described in detail.
A kind of coating stent of medicine comprises support matrix 1, bioactivator layer, and described bioactivator layer is two-layer or three layers of medication coat; The bioactivator layer is microtubule stabilizer layer, immunosuppressant layer, the anticoagulant layer that is coated on the support matrix surface, and wherein the anticoagulant layer is an outermost layer; Described microtubule stabilizer layer is a taxol drug layer 2, and the immunosuppressant layer is a rapamycin medicine layer 3; Described anticoagulant layer is a heparin medicine layer 4.
Described medication coat be by with medicine dissolution in the solution of macromolecular material, used macromolecular material can be biodegradable, also can degrade, adopt the medicine coating method of dip-coating, plasma polymerization, sputter etc. to be coated on the support matrix 1.
As seen in Figure 1, the frame mode of drug stent is support matrix 1, taxol drug layer 2, rapamycin medicine layer 3, is double-layer structure.
As seen in Figure 2, the frame mode of drug stent is support matrix 1, rapamycin medicine layer 3, taxol drug layer 2, is double-layer structure.
As seen in Figure 3, the frame mode of drug stent is support matrix 1 paclitaxel and rapamycin hybrid medicine layer 5, heparin medicine layer 4, is double-layer structure.
As seen in Figure 4, the frame mode of drug stent is support matrix 1, taxol drug layer 2, rapamycin medicine layer 3, heparin medicine layer 4, is three-decker.
Claims (5)
1. a coating stent of medicine comprises support matrix, bioactivator layer, it is characterized in that, described bioactivator layer is two-layer or three layers of medication coat.
2. coating stent of medicine according to claim 1 is characterized in that, described bioactivator layer is microtubule stabilizer layer and the immunosuppressant layer that is coated on the support matrix surface.
3. coating stent of medicine according to claim 1 is characterized in that, described bioactivator layer is microtubule stabilizer layer and immunosuppressant layer and the anticoagulant layer that is coated on the support matrix surface, and wherein the anticoagulant layer is an outermost layer.
4. according to claim 2 or 3 described coating stent of medicine, it is characterized in that described microtubule stabilizer layer is the taxol drug layer, the immunosuppressant layer is the rapamycin medicine layer.
5. coating stent of medicine according to claim 3 is characterized in that, described anticoagulant layer is the heparin medicine layer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2008200173570U CN201179222Y (en) | 2008-02-03 | 2008-02-03 | Medicament coating bracket |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2008200173570U CN201179222Y (en) | 2008-02-03 | 2008-02-03 | Medicament coating bracket |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN201179222Y true CN201179222Y (en) | 2009-01-14 |
Family
ID=40248724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNU2008200173570U Expired - Fee Related CN201179222Y (en) | 2008-02-03 | 2008-02-03 | Medicament coating bracket |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN201179222Y (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101843531A (en) * | 2010-05-25 | 2010-09-29 | 天健医疗科技(苏州)有限公司 | Medicament coated thrombus filter |
| CN101874907A (en) * | 2009-04-30 | 2010-11-03 | 科迪斯公司 | Dual drug stent |
| CN102552992A (en) * | 2011-09-22 | 2012-07-11 | 上海微特生物技术有限公司 | Multilayered composite tube, manufacturing method thereof, and application thereof |
| CN104107459A (en) * | 2014-04-22 | 2014-10-22 | 吉林大学 | Degradable polymer coating support with sequential response function, and making method thereof |
| CN108744071A (en) * | 2018-08-20 | 2018-11-06 | 南京永明医疗器械有限公司 | A kind of multi-functional coatings and preparation method of biodegradable polymer stent |
-
2008
- 2008-02-03 CN CNU2008200173570U patent/CN201179222Y/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101874907A (en) * | 2009-04-30 | 2010-11-03 | 科迪斯公司 | Dual drug stent |
| CN101874907B (en) * | 2009-04-30 | 2016-07-06 | 科迪斯公司 | dual drug stent |
| CN101843531A (en) * | 2010-05-25 | 2010-09-29 | 天健医疗科技(苏州)有限公司 | Medicament coated thrombus filter |
| CN102552992A (en) * | 2011-09-22 | 2012-07-11 | 上海微特生物技术有限公司 | Multilayered composite tube, manufacturing method thereof, and application thereof |
| CN102552992B (en) * | 2011-09-22 | 2014-06-11 | 上海微特生物技术有限公司 | Multilayered composite tube, manufacturing method thereof, and application thereof |
| CN104107459A (en) * | 2014-04-22 | 2014-10-22 | 吉林大学 | Degradable polymer coating support with sequential response function, and making method thereof |
| CN108744071A (en) * | 2018-08-20 | 2018-11-06 | 南京永明医疗器械有限公司 | A kind of multi-functional coatings and preparation method of biodegradable polymer stent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ma et al. | Paclitaxel/sirolimus combination coated drug-eluting stent: in vitro and in vivo drug release studies | |
| CN201179222Y (en) | Medicament coating bracket | |
| CN101365447A (en) | Pharmaceuticals compositions containing nanomaterials useful for treating restenotic lesions | |
| JP2012500660A5 (en) | ||
| CN105833358B (en) | Intracranial drug eluting stent system and preparation method thereof | |
| JP5329435B2 (en) | Coronary stent with asymmetric drug release controlled coating | |
| CN103948975B (en) | A kind of targeted drug release gets involved class medical apparatus and instruments and preparation method thereof | |
| CN101199872A (en) | Double medicament controlled-release coating micropore ACS bracket | |
| CN106806948B (en) | Application of PI3K/mTOR dual inhibitor | |
| JP2014531933A (en) | Intervention medical device and manufacturing method thereof | |
| CN102940543A (en) | Combined medical instrument formed by drug coated balloon and stent | |
| JP2014530058A (en) | Intervention medical device and manufacturing method thereof | |
| CN101279112A (en) | Intravascular stent with PLGA blend medicament eluting surface coating | |
| EP1641502A1 (en) | Medical devices and methods for inhibiting smooth muscle cell proliferation | |
| CN201734994U (en) | Medicine-loading coronal artery bracket capable of loading medicine in the manner of gradient concentration | |
| JP2004222953A (en) | Indwelling stent | |
| CN101455863A (en) | Medicine eluting coronary stent | |
| CN202191582U (en) | Medicine balloon dilating catheter | |
| CN104107459A (en) | Degradable polymer coating support with sequential response function, and making method thereof | |
| EP3520789B1 (en) | New use of amlexanox | |
| CN106618821B (en) | A kind of intravascular stent for preventing reangiostenosis and preparation method thereof | |
| CN100371032C (en) | Re-stricture preventing medicinal sustained releasing bracket and its preparation | |
| CN108744071A (en) | A kind of multi-functional coatings and preparation method of biodegradable polymer stent | |
| CN101496813B (en) | Applicance of combination in drug coating of preparing anti-hyperblastosis (vascular restenosis) support | |
| JP2006523235A (en) | Apparatus, method and composition for preventing restenosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090114 Termination date: 20100203 |